Registration of Human Drug
Compounding Outsourcing Facilities under section 503B of the FFDCA
and Associated fees under section 744K
Extension without change of a currently approved collection
No
Regular
12/01/2023
Requested
Previously Approved
36 Months From Approved
12/31/2023
206
116
861
429
0
0
This information collection helps to
support implementation of section 503B of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) and the Drug Quality and Security
Act (DQSA) regarding the registration of human drug compounding
outsourcing facilities. The information collection also implements
provisions applicable to registered outsourcing facilities and the
assessment and remission of user fees under section 744K of the
FD&C Act.
US Code:
21 USC 301 et seq. Name of Law: Federal Food, Drug, and
Cosmetic Act
The information collection
reflects an increase in the number of annual registrations, but a
decrease in reinspection fee submissions. The adjustments result in
an increase of 90 responses and 432 hours annually.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.